Benjamin Diamond

Benjamin Diamond practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Benjamin Diamond's NPI, 1992199822, was assigned on March 28, 2015. Benjamin Diamond graduated from Boston University School Of Medicine in 2015. Benjamin Diamond holds Florida license ME150421.

Benjamin Diamond's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Benjamin Diamond's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Benjamin Diamond practices. Vendor and product names are available with a free account.

Hematology and oncology is Benjamin Diamond's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Benjamin Diamond is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Benjamin Diamond's licenses on file in 2 states: Florida and New York.

Dmand AI lists immune deficiency disease and multiple myeloma among the conditions Benjamin Diamond treats.

CMS data shows 387 Medicare services from Benjamin Diamond across 3 procedure codes in 2024, for 71 Medicare patients. Medicare paid $24,763 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 71 Medicare patients who saw Benjamin Diamond in 2024. The largest group is 65 to 74, with 30 patients. 69% of them have high blood pressure, and 65% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Benjamin Diamond's median patient age at 73, with 49% women.

In 2024, Benjamin Diamond wrote 196 Medicare Part D claims for 32 patients. 84% of them were for generic drugs. CMS names the drug for 146 of them, across 6 drugs with 11 or more claims each, at $17,080 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Benjamin Diamond for performance year 2024, reported as part of a group. Benjamin Diamond accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Benjamin Diamond as offering telehealth.

Dmand AI links 52 papers to Benjamin Diamond, published from 2019 to 2025. 2021 was the busiest year, with 15. The most frequent topics are Multiple Myeloma, Lenalidomide and Antineoplastic Combined Chemotherapy Protocols. Benjamin Diamond has published most often in bioRxiv. Benjamin Diamond's most frequent co-authors are Francesco Maura, MD, Kylee Maclachlan and Alexander M. Lesokhin, MD.

Dmand AI links Benjamin Diamond to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Multiple Myeloma and Blood Protein Disorders.

CMS Open Payments shows 28 general payments to Benjamin Diamond from 4 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 95% of the total. Janssen Research & Development, LLC paid the most, $28,250.

Benjamin Diamond graduated from Boston University School Of Medicine in 2015.

Benjamin Diamond is in network with 10 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Aetna. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.